RxDoctor Payments Data

De'arco McCreary, MD

Internal Medicine · Mobile, ALNPI 1750624508

Payments from drug & device makers

$1,634in general payments, 2019–2025

Across 89 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$419
  • AstraZeneca$312
  • Daiichi Sankyo Inc.$264
  • AbbVie$241
  • GSK$156
  • Bayer$63
  • plus $178 from 6 others

What the payments were for

  • Food & beverage$1,634100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,634 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$40,757
Medicare patients
77
Services billed
1,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide157$217,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$43,550
FarxigaDapagliflozin Propanediol33$37,689
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$35,467
JanuviaSitagliptin Phosphate28$35,143
MounjaroTirzepatide28$30,472
JardianceEmpagliflozin21$27,725
RybelsusSemaglutide12$25,214
LinzessLinaclotide35$24,020
EliquisApixaban18$18,460
XareltoRivaroxaban16$16,188
MyrbetriqMirabegron18$15,977
VascepaIcosapent Ethyl13$13,678
Atorvastatin Calcium439$4,402
Humalog Kwikpen U-100Insulin Lispro23$3,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$419$242,972169 claims
GSKTrelegy Ellipta$156$43,55059 claims
AstraZenecaFarxiga$312$37,68933 claims
Lilly USA, LLCMounjaro$50$30,47228 claims
Boehringer IngelheimJardiance$15$27,72521 claims
AbbVieLinzess$241$24,02035 claims
PfizerEliquis$38$18,46018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →